Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2025)

Tarsus Pharmaceuticals has reported Cost of Revenue over the past 5 years, most recently at $10.9 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $10.9 million for Q4 2025, up 121.82% from a year ago — trailing twelve months through Dec 2025 was $30.7 million (up 139.23% YoY), and the annual figure for FY2025 was $30.7 million, up 139.23%.
  • Cost of Revenue for Q4 2025 was $10.9 million at Tarsus Pharmaceuticals, up from $8.3 million in the prior quarter.
  • Over the last five years, Cost of Revenue for TARS hit a ceiling of $10.9 million in Q4 2025 and a floor of -$24000.0 in Q4 2021.
  • Median Cost of Revenue over the past 5 years was $1.3 million (2021), compared with a mean of $2.8 million.
  • Peak annual rise in Cost of Revenue hit 1766.67% in 2022, while the deepest fall reached 97.46% in 2022.
  • Tarsus Pharmaceuticals' Cost of Revenue stood at -$24000.0 in 2021, then skyrocketed by 1766.67% to $400000.0 in 2022, then soared by 204.0% to $1.2 million in 2023, then soared by 305.1% to $4.9 million in 2024, then skyrocketed by 121.82% to $10.9 million in 2025.
  • The last three reported values for Cost of Revenue were $10.9 million (Q4 2025), $8.3 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.